|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PPP1R12A |
Gene summary for PPP1R12A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PPP1R12A | Gene ID | 4659 |
| Gene name | protein phosphatase 1 regulatory subunit 12A | |
| Gene Alias | GUBS | |
| Cytomap | 12q21.2-q21.31 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | B2RAH5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4659 | PPP1R12A | CA_HPV_1 | Human | Cervix | CC | 3.14e-04 | 1.81e-03 | 0.0264 |
| 4659 | PPP1R12A | CCI_2 | Human | Cervix | CC | 3.48e-07 | 1.27e+00 | 0.5249 |
| 4659 | PPP1R12A | CCI_3 | Human | Cervix | CC | 3.20e-07 | 8.49e-01 | 0.516 |
| 4659 | PPP1R12A | CCII_1 | Human | Cervix | CC | 7.12e-03 | -3.49e-01 | 0.3249 |
| 4659 | PPP1R12A | L1 | Human | Cervix | CC | 2.68e-03 | -1.34e-01 | 0.0802 |
| 4659 | PPP1R12A | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.44e-14 | -6.21e-01 | 0.0155 |
| 4659 | PPP1R12A | HTA11_3361_2000001011 | Human | Colorectum | AD | 9.09e-03 | -5.55e-01 | -0.1207 |
| 4659 | PPP1R12A | HTA11_696_2000001011 | Human | Colorectum | AD | 7.27e-07 | -3.69e-01 | -0.1464 |
| 4659 | PPP1R12A | HTA11_866_2000001011 | Human | Colorectum | AD | 8.80e-04 | -3.27e-01 | -0.1001 |
| 4659 | PPP1R12A | HTA11_7862_2000001011 | Human | Colorectum | AD | 1.56e-02 | -6.34e-01 | -0.0179 |
| 4659 | PPP1R12A | HTA11_866_3004761011 | Human | Colorectum | AD | 3.69e-09 | -6.11e-01 | 0.096 |
| 4659 | PPP1R12A | HTA11_8622_2000001021 | Human | Colorectum | SER | 2.83e-02 | -6.17e-01 | 0.0528 |
| 4659 | PPP1R12A | HTA11_10711_2000001011 | Human | Colorectum | AD | 2.19e-02 | -5.33e-01 | 0.0338 |
| 4659 | PPP1R12A | HTA11_7696_3000711011 | Human | Colorectum | AD | 7.53e-14 | -5.00e-01 | 0.0674 |
| 4659 | PPP1R12A | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 4.86e-04 | 8.40e-01 | 0.3487 |
| 4659 | PPP1R12A | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.87e-06 | -3.39e-01 | 0.3859 |
| 4659 | PPP1R12A | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.38e-19 | -5.75e-01 | 0.3005 |
| 4659 | PPP1R12A | A015-C-203 | Human | Colorectum | FAP | 6.94e-34 | -4.51e-01 | -0.1294 |
| 4659 | PPP1R12A | A015-C-204 | Human | Colorectum | FAP | 1.17e-03 | -2.67e-01 | -0.0228 |
| 4659 | PPP1R12A | A014-C-040 | Human | Colorectum | FAP | 1.93e-05 | -3.58e-01 | -0.1184 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00069139 | Cervix | CC | nucleocytoplasmic transport | 71/2311 | 301/18723 | 4.04e-08 | 2.54e-06 | 71 |
| GO:00511699 | Cervix | CC | nuclear transport | 71/2311 | 301/18723 | 4.04e-08 | 2.54e-06 | 71 |
| GO:00468229 | Cervix | CC | regulation of nucleocytoplasmic transport | 31/2311 | 106/18723 | 2.68e-06 | 7.87e-05 | 31 |
| GO:00323868 | Cervix | CC | regulation of intracellular transport | 71/2311 | 337/18723 | 3.70e-06 | 9.74e-05 | 71 |
| GO:00064708 | Cervix | CC | protein dephosphorylation | 60/2311 | 281/18723 | 1.33e-05 | 2.68e-04 | 60 |
| GO:00436668 | Cervix | CC | regulation of phosphoprotein phosphatase activity | 18/2311 | 58/18723 | 1.40e-04 | 1.70e-03 | 18 |
| GO:003530310 | Cervix | CC | regulation of dephosphorylation | 31/2311 | 128/18723 | 1.52e-04 | 1.83e-03 | 31 |
| GO:003530410 | Cervix | CC | regulation of protein dephosphorylation | 24/2311 | 90/18723 | 1.73e-04 | 2.04e-03 | 24 |
| GO:00109218 | Cervix | CC | regulation of phosphatase activity | 22/2311 | 84/18723 | 4.18e-04 | 4.23e-03 | 22 |
| GO:00163117 | Cervix | CC | dephosphorylation | 73/2311 | 417/18723 | 1.23e-03 | 9.87e-03 | 73 |
| GO:00109223 | Cervix | CC | positive regulation of phosphatase activity | 11/2311 | 34/18723 | 1.87e-03 | 1.39e-02 | 11 |
| GO:00094109 | Cervix | CC | response to xenobiotic stimulus | 78/2311 | 462/18723 | 2.39e-03 | 1.70e-02 | 78 |
| GO:00325162 | Cervix | CC | positive regulation of phosphoprotein phosphatase activity | 8/2311 | 21/18723 | 2.44e-03 | 1.71e-02 | 8 |
| GO:0006913 | Colorectum | AD | nucleocytoplasmic transport | 102/3918 | 301/18723 | 1.00e-07 | 4.85e-06 | 102 |
| GO:0051169 | Colorectum | AD | nuclear transport | 102/3918 | 301/18723 | 1.00e-07 | 4.85e-06 | 102 |
| GO:0032386 | Colorectum | AD | regulation of intracellular transport | 109/3918 | 337/18723 | 5.33e-07 | 1.95e-05 | 109 |
| GO:0016311 | Colorectum | AD | dephosphorylation | 123/3918 | 417/18723 | 1.84e-05 | 3.82e-04 | 123 |
| GO:0046822 | Colorectum | AD | regulation of nucleocytoplasmic transport | 41/3918 | 106/18723 | 2.17e-05 | 4.33e-04 | 41 |
| GO:0006470 | Colorectum | AD | protein dephosphorylation | 88/3918 | 281/18723 | 2.56e-05 | 4.89e-04 | 88 |
| GO:0035303 | Colorectum | AD | regulation of dephosphorylation | 46/3918 | 128/18723 | 6.20e-05 | 1.04e-03 | 46 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0520516 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
| hsa0451010 | Cervix | CC | Focal adhesion | 59/1267 | 203/8465 | 1.53e-07 | 1.84e-06 | 1.09e-06 | 59 |
| hsa0481016 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
| hsa049218 | Cervix | CC | Oxytocin signaling pathway | 34/1267 | 154/8465 | 1.12e-02 | 3.42e-02 | 2.02e-02 | 34 |
| hsa046115 | Cervix | CC | Platelet activation | 28/1267 | 124/8465 | 1.50e-02 | 4.45e-02 | 2.63e-02 | 28 |
| hsa0520517 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
| hsa0451014 | Cervix | CC | Focal adhesion | 59/1267 | 203/8465 | 1.53e-07 | 1.84e-06 | 1.09e-06 | 59 |
| hsa0481017 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
| hsa0492111 | Cervix | CC | Oxytocin signaling pathway | 34/1267 | 154/8465 | 1.12e-02 | 3.42e-02 | 2.02e-02 | 34 |
| hsa0461113 | Cervix | CC | Platelet activation | 28/1267 | 124/8465 | 1.50e-02 | 4.45e-02 | 2.63e-02 | 28 |
| hsa05205 | Colorectum | AD | Proteoglycans in cancer | 70/2092 | 205/8465 | 1.37e-03 | 8.46e-03 | 5.39e-03 | 70 |
| hsa04810 | Colorectum | AD | Regulation of actin cytoskeleton | 75/2092 | 229/8465 | 3.36e-03 | 1.76e-02 | 1.12e-02 | 75 |
| hsa04510 | Colorectum | AD | Focal adhesion | 67/2092 | 203/8465 | 4.40e-03 | 2.17e-02 | 1.38e-02 | 67 |
| hsa052051 | Colorectum | AD | Proteoglycans in cancer | 70/2092 | 205/8465 | 1.37e-03 | 8.46e-03 | 5.39e-03 | 70 |
| hsa048101 | Colorectum | AD | Regulation of actin cytoskeleton | 75/2092 | 229/8465 | 3.36e-03 | 1.76e-02 | 1.12e-02 | 75 |
| hsa045101 | Colorectum | AD | Focal adhesion | 67/2092 | 203/8465 | 4.40e-03 | 2.17e-02 | 1.38e-02 | 67 |
| hsa052052 | Colorectum | SER | Proteoglycans in cancer | 58/1580 | 205/8465 | 4.37e-04 | 3.82e-03 | 2.77e-03 | 58 |
| hsa048102 | Colorectum | SER | Regulation of actin cytoskeleton | 60/1580 | 229/8465 | 2.74e-03 | 2.02e-02 | 1.47e-02 | 60 |
| hsa052053 | Colorectum | SER | Proteoglycans in cancer | 58/1580 | 205/8465 | 4.37e-04 | 3.82e-03 | 2.77e-03 | 58 |
| hsa048103 | Colorectum | SER | Regulation of actin cytoskeleton | 60/1580 | 229/8465 | 2.74e-03 | 2.02e-02 | 1.47e-02 | 60 |
| Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PPP1R12A | SNV | Missense_Mutation | c.2279N>A | p.Arg760Lys | p.R760K | O14974 | protein_coding | tolerated(0.11) | possibly_damaging(0.745) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| PPP1R12A | SNV | Missense_Mutation | c.1072N>A | p.Glu358Lys | p.E358K | O14974 | protein_coding | tolerated(0.09) | probably_damaging(0.98) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| PPP1R12A | SNV | Missense_Mutation | c.961N>C | p.Glu321Gln | p.E321Q | O14974 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-AO-A0J4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| PPP1R12A | deletion | Frame_Shift_Del | c.882delA | p.Lys294AsnfsTer8 | p.K294Nfs*8 | O14974 | protein_coding | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| PPP1R12A | SNV | Missense_Mutation | novel | c.580N>T | p.Arg194Trp | p.R194W | O14974 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| PPP1R12A | SNV | Missense_Mutation | c.2614N>C | p.Asp872His | p.D872H | O14974 | protein_coding | deleterious(0.01) | probably_damaging(0.995) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
| PPP1R12A | SNV | Missense_Mutation | c.995N>T | p.Ser332Phe | p.S332F | O14974 | protein_coding | deleterious(0.04) | benign(0.172) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD | |
| PPP1R12A | SNV | Missense_Mutation | c.2614N>C | p.Asp872His | p.D872H | O14974 | protein_coding | deleterious(0.01) | probably_damaging(0.995) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PPP1R12A | SNV | Missense_Mutation | novel | c.2552G>A | p.Arg851Lys | p.R851K | O14974 | protein_coding | deleterious(0.01) | probably_damaging(0.931) | TCGA-DG-A2KK-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| PPP1R12A | SNV | Missense_Mutation | c.2081N>C | p.Arg694Thr | p.R694T | O14974 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |